Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Abstract

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

• Authors: Elizabeth J Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J Müller, Henry M Dunnenberger, Wasun Chantratita, Barry Goldspiel, Yuan-Tsong Chen, Bruce C Carleton, Alfred L George Jr, Taisei Mushiroda, Teri Klein, Roseann S Gammal, Munir Pirmohamed
• Journal: Clinical pharmacology and therapeutics (Clin Pharmacol Ther) Vol. 103 Issue 4 Pg. 574-581 (04 2018) ISSN: 1532-6535 [Electronic] United States
• PMID: 29392710 (Publication Type: Journal Article, Practice Guideline, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2018 American Society for Clinical Pharmacology and Therapeutics.

Chemical References

• Anticonvulsants
• HLA-B Antigens
• Carbamazepine
• Oxcarbazepine

Topics

• Anticonvulsants (pharmacology)
• Carbamazepine (pharmacology)
• Drug-Related Side Effects and Adverse Reactions (genetics, prevention & control)
• HLA-B Antigens (genetics)
• Humans
• Oxcarbazepine (pharmacology)
• Pharmacogenetics (methods, standards)